| Cash flow (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | 3.61B | 695.00M | 1.82B | 186.00M | 938.00M | 1.29B | -22.00M | 1.56B |
| Depreciation and amortization | 194.00M | 188.00M | 203.00M | 192.00M | 186.00M | 181.00M | 206.00M | 191.00M |
| Stock-based compensation | 166.00M | 444.00M | 157.00M | 209.00M | 179.00M | 410.00M | 164.00M | 181.00M |
| Cash from operations | 3.44B | 3.83B | 5.22B | 7.02B | 5.15B | 1.64B | 7.05B | 5.45B |
| Capital expenditure | -322.00M | -265.00M | -329.00M | -381.00M | -269.00M | -235.00M | -291.00M | -249.00M |
| Free cash flow | 3.11B | 3.56B | 4.89B | 6.64B | 4.88B | 1.40B | 6.76B | 5.20B |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -204.00M | 0 | -8.29B |
| Cash from investing | -1.20B | -574.00M | -1.46B | -3.26B | -1.18B | -735.00M | -1.87B | -8.26B |
| Dividends paid | -3.07B | -3.09B | -2.91B | -2.91B | -2.91B | -2.92B | -2.75B | -2.75B |
| Share buybacks | -9.00M | -1.49B | -3.00M | -4.00M | -12.00M | -961.00M | -358.00M | -17.00M |
| Net debt issued | 0 | 7.99B | 0 | 0 | 0 | 3.99B | 2.00B | 0 |
| Cash from financing | -5.05B | 919.00M | -4.17B | -4.59B | -2.71B | -1.26B | -6.86B | -3.07B |
| Net change in cash | -2.82B | 4.16B | -400.00M | -838.00M | 1.29B | -349.00M | -1.73B | -5.87B |
From AbbVie's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.